Palisade Bio, Inc. · NASDAQ:PALI

Palisade Bio — Investor Presentation (April 2024)

25 slides from Palisade Bio's investor presentation, April 2024

  1. Slide 1: Transforming the Treatment of Autoimmune, Inflammatory and Fibrotic Diseases

    palisadebio.com NASDAQ CM: PALI Transforming the Treatment of Autoimmune, Inflammatory and Fibrotic Diseases Corporate Presentation April 2024

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and pre-clinical and clinical development plans, expected near and long

  3. Slide 3: Investment Key Highlights

    Investment KEY HIGHLIGHTS Broad pipeline targeting Highlights high-value IBD market Clinically validated PDE4 target utilized Developing novel therapeutics for by multiple Big Pharma players serious autoimmune, inflammatory and fibrotic diseases, with a targeted Rapidly advancing towards Phase 1 ini

  4. Slide 4: Our Oral Development Pipeline

    Our Oral Development Pipeline Oral Prodrug Therapies that Act Locally at Site of Disease IND/CTA- Program Discovery Phase 1 Phase 2 Phase 3 Highlights Enabling Ongoing IND/CTA-enabling tox studies PALI-2108 Ulcerative Colitis Rapidly advancing towards IND/CTA filing in 2024 Lead optimization complet

  5. Slide 5: Big Pharma is Active in IBD and Spending Big Dollars for Earlier Stage Programs

    Big Pharma is Active in IBD and Spending Big Dollars for Earlier Stage Programs Company Acquirer Date Lead Asset Phase at Deal MOA Upfront Total Deal Royalties Current Status Anti-TL1A Oct 2023 RVT-3101 Phase 3 Ready Mab $7.1 Billion $7.2 Billion NA Phase 3 Prep Anti-TL1A Oct 2023 TEV'574 Phase 2b M

  6. Slide 6: Inflammatory Bowel Diseases (IBD)

    Inflammatory Bowel Diseases (IBD) Chronic Condition Characterized by Persistent Inflammation in the Digestive Tract Diagnosed in Early Adulthood with Alternating Periods of Activity and Remission Symptoms COLITIS Diarrhea CROHN’S Abdominal pain Fatigue Cramping Blood in your stool Reduced appetite F

  7. Slide 7: IBD is a Large and Growing Market

    IBD is a Large and Growing Market 2,3 CURRENT IBD MARKET Expected to Grow 1 to $20B by 2031 Ulcerative Colitis Crohn’s Disease Novel Therapeutics Demonstrating Safety and Efficacy are Likely to Gain Market Share 1.95 Million 1.63 Million Cases Cases Palisade Bio Has the Only PDE4 Under Development f

  8. Slide 8: The IBD Patient Journey

    ULCERATIVE COLITIS Of patients have moderate-to-severely ~40-50% The IBD active disease Of patients with active disease will 70% Patient Journey have active disease the next year Of patients in remission will have 30% active disease the next year Of patients with long-lasting UC and Patients and cli

  9. Slide 9: Current Standard-of-Care Therapies Have Limited Effectiveness

    Current Standard-of-Care Therapies Have Limited Effectiveness No Standard Regimen for Managing All IBD Patients The Approach to Treatment Needs to Be Tailored for the Individual CURRENT FACTORS THAT DETERMINE TREATMENT APPROACH TREATMENT APPROACH 5-ASA is generally first line for ulcerative colitis

  10. Slide 10: PALI-2108: Targeting Ulcerative Colitis

    PALI-2108 Targeting Ulcerative Colitis 10

  11. Slide 11: Ulcerative Colitis Competitive Landscape

    Ulcerative Colitis Competitive Landscape Most Effective Therapies Have Black Box Warning, New Therapies Are Not as Effective Placebo-Adjusted Overall Remission Route of Safety Drug Company Indication FDA Approval Clinical Remission Rate Administration Considerations Moderate-to-severely active UC wi

  12. Slide 12: Potential Future Ulcerative Colitis Competitive Landscape

    Potential Future Ulcerative Colitis Competitive Landscape UC Market is Expected to Evolve By 2028 with New Therapies We Believe PALI-2108 Has a Significant Advantage Over Current Projections and has Potential to Take Significant Market Share Placebo-Adjusted Overall Remission Route of Safety Drug Co

  13. Slide 13: PALI-2108: Our Differentiated Approach to Ulcerative Colitis

    PALI-2108: Our Differentiated Approach to Ulcerative Colitis Novel PDE4 Inhibitor Pre-IND/CTA Candidate Oral Prodrug Therapies That Act Locally at Site of Disease KEY DIFFERENTIATION  Oral Dosing  Locally Active  Limited Systemic Activity (improved safety)  Superior Cytokine Blocking Profile  P

  14. Slide 14: PALI-2108: Mechanism of Action

    Re vERY PALI-2108: Mechanism of Action — % ; Bacterial ‘ 3 % ° § | enzyme ae | , se > of : i. . etittn ©2225 sioactivation | " a e NON Tene 4 5 DAY ih PALI-2108 PALI-0008 SUPERIOR TNF-a S ue PDE4 INHIBITOR™§| BLOCKING PROFILE PDE4 IN ‘OR PRODRUG 2 - el . - ¥ (Gas Monocyte ' f @ Limiten systemic eg i

  15. Slide 15: PALI-2108 Data Highlights

    PALI-2108 Data Highlights DSS Mouse Proof of Efficacy Study  Exclusively selective for PDE4 limiting the potential for off-target effects  Isoenzyme inhibition profile comparable to marketed DAI (% AUC) anti-inflammatory and anti-fibrotic PDE4 inhibitor  20 times more potent as a TNFα inhibitor t

  16. Slide 16: PDE4 is an Established Dual Acting Anti-Inflammatory and Anti-Fibrotic Target

    PDE4 is an Established Dual Acting (Pleiotropic) Anti-Inflammatory and Anti-Fibrotic Target COPD (Roflumilast; AstraZeneca): Anti-fibrotic indications such as chronic obstructive pulmonary disease Psoriasis and Psoriatic Arthritis (Apremilast; Amgen): Anti- inflammatory indications validated by appr

  17. Slide 17: PALI-2108: Locally Active

    PALI-2108: Locally Active Potential to overcome systemic PDE4 toxicities of nausea and vomiting Compelling Efficacy Demonstrated in Multiple Phase 2 Studies with Systemic PDE4 Inhibitors but with Dose-Limiting Toxicity Mild-to-Moderate Active UC1 Moderate-to-Severely Active UC2 Placebo 25 mg group*

  18. Slide 18: PALI-2108 Development Plan Through Phase 1a/b

    PALI-2108 Development Plan Through Phase 1a/b Q2 Q3 Q4 Q1 Q2 Q3 Q4 H1 H2 2023 2023 2023 2024 2024 2024 2024 2025 2025 GMP Manufacturing IND/CTA-enabling Studies Regulatory Interactions IND/CTA Submission Phase 1a/b Initiation of Ph1 a/b Clinical Study First Patient In Topline Data 18

  19. Slide 19: Precision Medicine Approach

    Precision Medicine Approach Precision Medicine Approach for  Elevated express of PDE4 in chronic UC Selecting Patients Most Likely to patients correlates with disease activity by Mayo score1 Respond to PDE4 Therapy in UC  Elevated expression of inflammatory PROTEOMICS cytokines has been shown in c

  20. Slide 20: Significant IP Portfolio Through 2042

    Significant IP Portfolio Through 2042 Composition of Matter Patent Family Composition of Matter PCT/CA2021/050725 Coverage Until 2042+ National Phase Entry of PCT FDA Regulatory Exclusivity December 2022 Coverage for 8 Years National Phase Entry Potential to File Additional Patents US, Canada, China

  21. Slide 21: Program Team

    Program Team JD Finley, MT Mitch Jones, MD, PhD Joie Bernard, PhD Adarsh Patel, MS, MBA CEO CMO Sr. Director, Clinical and Assoc. Director, Technical Operations Translational Research Christophe Mellon, PhD Jon Daniels, PhD Patrick Colin, B. Pharm, PhD CMC & Medicinal Chemistry Safety & Tox & Reg (C

  22. Slide 22: Clinical Advisory Board

    Clinical Advisory Board Bruce Sands MD, MS Florian Rieder, MD Dr. Burrill B. Crohn Professor of Medicine, Icahn School Associate Staff in the Department of Gastroenterology, of Medicine at Mount Sinai and System Chief, Division Hepatology, and Nutrition, as well as an Investigator in of Gastroentero

  23. Slide 23: Financial Snapshot

    Financial Snapshot Strong Financial Position with Cash to Fund Operations into First Quarter of 2025 $12.5M Cash As of December 31, 2023 ~$5.1M ~198K Cash balance does not include $2.5M in Gross Market Cap 1 Volume 1 Proceeds from Exercise of Previously Issued Warrants 23 1: As of April 8, 2024, wit

  24. Slide 24: Investment Summary

    Oral therapeutics addressing UC and CD in high-value IBD market Investment Growing body of data demonstrating locally Summary acting, locally acting approach improves efficacy and safety PDE4 target validated by multiple approved products Developing novel therapeutics for serious autoimmune, inflamm

  25. Slide 25: Transforming the Treatment of Autoimmune, Inflammatory and Fibrotic Diseases

    palisadebio.com NASDAQ CM: PALI Transforming the Treatment of Autoimmune, Inflammatory and Fibrotic Diseases Investor Relations: JTC Team, LLC 833-475-8247 [email protected]

Palisade Bio — Investor Presentation (April 2024) on 6ix